Information

7: Cancer Genetics - Biology

7: Cancer Genetics - Biology


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Cancer is a group of diseases that exhibit uncontrolled growth, invasion of adjacent tissues, and sometimes metastasis (the movement of cancer cells through the blood or lymph). In cancer cells, the regulatory mechanisms that control cell division and limit abnormal growth have been disrupted, usually by the accumulation of several mutations. Cancer is therefore essentially a genetic disease. Although some cancer-­‐related mutations may be heritable, most cancers are sporadic, meaning they arise from new mutations that occur in the individual who has the disease. In this chapter we will examine the connection between cancer and genes.

Figure (PageIndex{1}): Stained histological section of a neuroblastoma in an adrenal gland. (Flickr-Ed Uthman-CC:AS)


Cancer Genetics and Genomics

The Cancer Genetics and Genomics (CGG) Program seeks to better understand the cancer genome and leverage novel insights into cancer genomics to improve outcomes for cancer patients. The three main research themes of the CGG Program include: (1) invention of cancer genome and transcriptome profiling technology (2) development of computational tools and resources for interpreting cancer genomes and transcriptomes and (3) implementation of high-throughput genetic-screening technologies to comprehensively map cancer dependencies.

Program Co-leaders

The Cancer Genetics and Genomics Program seeks to advance our understanding of the cancer genome through genetic, technological, and computational innovations. In fitting with the mission of the Cold Spring Harbor Laboratory (CSHL) Cancer Center as an NCI-designated Basic Laboratory Cancer Center, the Program focuses on fundamental research to better understand the genetic alterations that drive cancer development and progression. The research themes in the CGG Program are built on the premise that a deeper characterization of the cancer genome will improve the survival and quality of life for patients with cancer, and Program members are translating insights made about the cancer genome into novel diagnostic and prognostic biomarkers. In addition, the Program maintains a focus on the development of new genomic technologies and computational tools, which are being used to analyze the cancer genome, aid in cancer diagnosis, and discover novel cancer dependencies.

Over the last five years, several Program investigators have developed technologies for profiling cancer genomes and transcriptomes. These include diverse methods for in situ sequencing of RNA in tumors, methods to find structural variants, and single-cell analysis methods. Members are also developing computational tools for genome and transcriptome analysis, which reflects the interdisciplinary approach of members with expertise in both traditional bench research and computational biology. In addition, Program members are using high-throughput genetic-screening approaches for therapeutic target discovery and validation. This theme makes use of multiplexed screening technologies, pioneered by Program members, for high-throughput assessment of gene functions. To support these efforts, Program members are developing computational algorithms for interpreting the complex datasets generated through these studies. Several Cancer Center Shared Resources are pivotal for the discovery research in this Program, including the Flow Cytometry, Microscopy, and Sequencing Technologies & Analysis Shared Resources.

Research matters

June 8, 2021

Innovative research and educational activities never stopped during the COVID-19 pandemic.

How an antiviral drug can flatten the curve…in your cells

April 9, 2021

Scientists figured out how an antiviral drug in clinical trials combats COVID-19 and it’s better than expected.

CSHL wins ACS grant based on crowdsourced support

February 4, 2021

CSHL Fellow Jason Sheltzer received a grant through the American Cancer Society’s new social media platform TheoryLab™.

Birds of a feather do flock together

November 17, 2020

Researchers found a genetic mechanism for how brand new species acquire distinct traits.

Women’s Partnership luncheon raises $150,000 for research

September 29, 2020

The nineteenth annual Women’s Partnership for Science luncheon was held with social distancing to support CSHL women researchers.

Fuerth wins BBRF Young Investigator Grant in neuro research

September 25, 2020

Daniel Fuerth, a postdoctoral fellow in Assistant Professor Je Lee’s lab,will study the transfer of genetic material between neurons in the brain.

New genetic research to understand racial disparity in cancers

September 8, 2020

Cold Spring Harbor Laboratory will study the genetic contributions of ethnicity to colon, endometrial, and pancreas cancers in African Americans.

Why we’re a lot better at fighting cancer than we realized

August 12, 2020

Using data mining techniques, doctors have discovered dozens of anti-tumor drugs hiding in plain sight.

ENCODE3: Interpreting the human and mouse genomes

July 29, 2020

Researchers report on 900,000 regulatory elements in our genomes that could influence our health.

Smoking increases SARS-CoV-2 receptors in the lung

May 18, 2020

An increase in lung ACE2 may explain why smokers are particularly vulnerable to COVID-19.

Tuveson and Wigler elected AACR Academy Fellows

May 12, 2020

CSHL Cancer Center Director David Tuveson and Professor Michael Wigler were chosen as 2020 Fellows of the AACR Academy.

Dog adaptations are like brain adaptations

To understand autism, CSHL Professor Michael Wigler thinks about how biological systems adapt over generations.

The status of autism research&mdashin verse

April 29, 2020

CSHL Professor Michael Wigler drafted a poem explaining what we know and what we need to learn about autism.

Predicting the evolution of genetic mutations

April 14, 2020

CSHL quantitative biologists have designed a computational approach for predicting the evolution of a rapidly mutating virus or cancer.

A science career path: David McCandlish

April 10, 2020

Assistant Professor David McCandlish is a quantitative biologist who walks the line between advanced mathematics and the life sciences at CSHL.

Carol Greider: Nobel Prize-winning rogue biologist

March 31, 2020

CSHL alumna Carol Greider won the Nobel Prize and is a champion for diversity. But her dyslexia almost derailed her career before it began.

New faculty Jeff Boyd studies breast cancer genomics

March 26, 2020

Professor Jeff Boyd joins the CSHL faculty, studying the growth and spread of breast cancer.

Extra chromosomes in cancers can be good or bad

February 24, 2020

Extra chromosomes are typical in cancerous tumor cells, but not all extra copies promote cancer growth.

The non-human living inside of you

January 9, 2020

A large part of human DNA doesn’t aid the normal workings of the body. This “junk DNA” contains ancient viruses that may spur diseases like ALS.

Ann Lin named in Forbes 30 Under 30 list for 2020

December 16, 2019

Ann Lin, a former intern in CSHL Fellow Jason Sheltzer’s lab, has been named a top entrepreneur on the Forbes 30 Under 30 list.

Bridge to education

December 15, 2019

CSHL’s DNA Learning Center builds new bridges between unique science education and diverse groups.

CSHL investigators rank among world’s most highly cited

December 11, 2019

Seven researchers affiliated with CSHL are among the scientists producing the top 1 percent of the most highly-cited research in the world.

Making sense of the genome…at last

December 6, 2019

Quantitative biologists like Cold Spring Harbor Laboratory’s Adam Siepel are finally making sense of the flood of data contained in the human genome.

The Lab partners with award-winning magazine

December 6, 2019

Nautilus, an award-winning science magazine, has partnered with CSHL to bring the story of the lab’s scientists and research to a brand-new audience.

Research profile: Adam Siepel

November 12, 2019

Adam Siepel, Chair of the Simons Center for Quantitative Biology, uses advanced computational methods to solve complex biological questions.

A home like no other, Cold Spring Harbor Laboratory

November 7, 2019

Hear why our campus, our community, and our collaborative nature makes us a place that so many scientists call "home."

Scientists take action to prevent sexual harassment and bias

November 7, 2019

Scientists gathered at Banbury Center last year to discuss ways to prevent gender bias and sexual harassment in science.

Nobel laureate William Kaelin draws a crowd

October 29, 2019

Nobel laureate and cancer researcher William Kaelin holds a seminar on his award-winning research at CSHL.

Seeking better treatment for ALS, Lou Gehrig’s disease

October 29, 2019

Researchers found that ‘jumping genes’ were de-silenced in post-mortem tissue samples of ALS patients.

Peter Koo wants to understand how machines learn biology

September 20, 2019

Dr. Peter Koo joins the CSHL faculty as an assistant professor. His focus is on exploring how artificial intelligence integrates with biology and genomics.

Cancer drugs don’t always work as intended, researchers warn

September 11, 2019

Ten experimental cancer drugs kill tumors in ways that are entirely different than how clinicians thought they did, revealing important insights.

Event: Public Lecture: Seeing With Sequencing

August 8, 2019

Come hear from three quantitative biologists as they discuss how they see with sequencing to solve mysteries ranging from the genetics of evolution.

Sheltzer wins Presidential Early Career Award

July 9, 2019

CSHL Fellow Jason Sheltzer is a recipient of the Presidential Early Career Award for Scientists and Engineers for his work in cancer research.

Lee awarded Chan Zuckerberg Initiative Human Cell Atlas grant

June 21, 2019

Assistant Professor Je H. Lee has been named a recipient of one of the Seed Networks for the Human Cell Atlas to study breast tissue.

An essay from the President: Biology for the planet

May 16, 2019

CSHL plant scientists are looking for solutions to the biggest questions in agriculture as environments are reshaped by climate change.

Seeing with sequencing&mdashA public lecture with three CSHL experts

April 19, 2019

Quantitative biologists discuss how physics, modern computing power, and a new perspective on biology can make sense of our complex genomes.

David McCandlish named Sloan Research Fellow

February 19, 2019

Assistant Professor David McCandlish has been named a 2019 Sloan Research Fellow for his promising work in the field of quantitative biology.

CSHL Fellow Jason Sheltzer wins innovation award

January 25, 2019

CSHL Fellow Jason Sheltzer wins the Damon Runyon-Rachleff Innovation Award for his work on cancer.

The year of CRISPR

December 26, 2018

A look at the various labs across CSHL that utilize CRISPR in their research, and the groundbreaking discoveries they help uncover.

How does natural selection affect the genome?

December 18, 2018

Adam Siepel explains how natural selection can tell researchers how informative sifting through the complex human genome will be.

How much are we learning? Natural selection is science’s best critic

December 17, 2018

Researchers determine that natural selection and our evolutionary history may be the best guides for future research.

Taking uncertainty out of cancer prognosis

December 11, 2018

An analysis of 20,000 patients has revealed that copy number variations in specific gene sites can help predict how deadly a cancer will be.

Taking uncertainty out of cancer prognosis

December 11, 2018

CSHL Fellow Jason Sheltzer has analyzed nearly 20,000 cancer patient histories and genetic data to take the guesswork out of prognosis.

Molly Hammell wins CZI award for ALS study

December 5, 2018

Associate Professor Molly Hammell wins award for proposed study to find transposable elements that are implicated in ALS.

Base Pairs Episode 17: Genomes, justice, and the journey here

September 15, 2018

A look at how gene-mapping works, what scientists can tell by looking at your genome, and what it means for your privacy.

Genomes, justice, and the journey here

September 15, 2018

CSHL Professor W. Richard McCombie discusses genomic privacy and sequencing technology in this episode of Base Pairs.

Massive genome havoc in breast cancer is revealed

July 12, 2018

Researchers have made a highly detailed map of 20,000 structural variations in a cancer cell’s genome

Alexander Dobin dives into genomic data

June 8, 2018

Alexander Dobin joins the faculty as its newest assistant professor, working on the computational side of genomics research

A science writer’s quest to understand heredity

May 30, 2018

LabDish spoke with science writer Carl Zimmer about what he learned about heredity as he zig-zagged through CSHL while writing his new book.

Portrait of a Neuroscience Powerhouse

April 27, 2018

A relatively small neuroscience group at CSHL is having an outsized impact on a dynamic and highly competitive field

Base Pairs Episode 14.5: Medicine and mad scientists

April 16, 2018

A follow-up discussion with CSHL Fellow Jason Sheltzer from Base Pairs episode 14, “The cancer answer that wasn’t.”

The cancer answer that wasn’t

March 15, 2018

We look at the "reproducibility crisis" in science, with a cancer researcher discovering something he didn't expect while experimenting with MELK

Base Pairs Episode 14: The cancer answer that wasn’t

March 15, 2018

We look at the "reproducibility crisis" in science, with a cancer researcher discovering something he didn't expect while experimenting with MELK.

Science self-corrects: cancer gene does not pass reproducibility test

February 13, 2018

CSHL Fellow Jason Sheltzer and his research team use CRISPR to discover that MELK is not actually involved in cancer.

Autism genetics study calls attention to impaired motor skills, general cognitive impairment

February 7, 2018

New research on the genetic causes of autism calls attention to diminished motor skills and suggests the importance of broad cognitive impairment

Evolving sets of gene regulators explain some of our differences from other primates

January 29, 2018

What makes us different from our primate relatives? Gene regulation is one important evolutionary factor

Base Pairs Episode 13: A lesson in class

December 15, 2017

We share three stories about classification in life sciences and how genetic information is changing how we define important categories.

A lesson in class

December 15, 2017

In this episode of Base Pairs, we discuss how genetic information is changing how we define important categories.

New method to determine before surgery which prostate tumors pose a lethal threat

December 1, 2017

The news about prostate cancer can be confusing. It’s the third most common cancer type among Americans.

Next-gen cancer test

November 24, 2017

Knowing that cancers become lethal when they spread, investigators at Cold Spring Harbor Laboratory seek a way of detecting tumors much earlier

CRISPR helps scientists find cancer’s (true) weaknesses

August 23, 2017

Jennifer Doudna (co-discoverer of the CRISPR gene editing tool) and CSHL's Jason Sheltzer talk breast cancer research.

New statistical method finds shared ancestral gene variants involved in autism’s cause

June 21, 2017

Researchers find children with autism are genetically more like other autistic children than their unaffected siblings.

Reconstructing ancient human history from DNA

June 20, 2017

Free public lecture featuring Adam Siepel, Ph.D., CSHL Professor and Chair of the Simons Center for Quantitative Biology.

Base Pairs Episode 9.5: Redefining biologists, redefining genes

May 16, 2017

We talk with Molly Hammell about peering into deep space using a high-tech telescope, we also talk to Tom Gingeras about redefining the gene.

Redefining biologists, redefining genes

May 16, 2017

Drs. Molly Hammell and Thomas Gingeras talk about redefining what a biologist is and what genes are.

Base Pairs Episode 9: Dark matter of the genome, part 2

April 15, 2017

In this episode of Base Pairs, we question the mythos that is “junk DNA” and explore the mysterious non-coding portions of the genome.

Dark matter of the genome, part 2

April 15, 2017

This episode of Base Pairs deals with the myth of "junk DNA" and why scientists are interested in non-coding portions of the genome.

What is single-cell genome viewer?

March 31, 2017

Single-cell genome viewer is a graphical interface, integrating single-cell genomics and conventional pathology of tumors.

Research suggests a possible role for a storm of ‘jumping genes’ in ALS

March 27, 2017

New research demonstrates that some transposons are no longer effectively inhibited, resulting in a storm of jumping genes, leading to DNA damage.

What a real-life science test looks like

March 24, 2017

By revealing evidence that contradicts the rationale for a new cancer drug, a pair of student scientists learns firsthand that when you do science.

Dark matter of the genome, part 1

March 15, 2017

This episode of Base Pairs digs into "dark matter" a type of genetic information that could help scientists better understand diseases like

Base Pairs Bonus Episode: Molecules and a mission

January 27, 2017

In this bonus episode, we explain the molecules and the metaphor of our podcast name: Base Pairs.

Relationship between incorrect chromosome number and cancer is reassessed

January 13, 2017

CSHL and MIT colleagues report surprising results of experiments intended to explore the consequences of having too many or too few chromosomes.

Relationship between incorrect chromosome number and cancer is reassessed after surprising experiments

January 12, 2017

Pre-malignant aneuploid cells grew more slowly and formed smaller tumors than comparable cells with normal chromosome number, CSHL researchers found.

The 2016 Cold Spring Harbor Laboratory Double Helix Medal Dinner

December 2, 2016

Dr. Bruce Stillman, President and CEO, Cold Spring Harbor Laboratory, discusses the history of the Lab and current research in biology and genomics.

A theoretical physicist’s approach to breast cancer

October 21, 2016

Associate Professor Mickey Atwal explains how exploring numbers and patterns could lead to a new cancer treatment strategy.

Non-modern family

August 15, 2016

This episode on Base Pairs explores how genetic information to better understand human history.

Riding out of the shadows of ALS, toward better treatments

August 1, 2016

Graduate student Lisa Krug discusses her research and personal connection to ALS, and Ride for Life, a not-for-profit organization for ALS research.

ALS Ride for Life comes to Cold Spring Harbor Laboratory

May 23, 2016

CSHL gathered to welcome Chris Pendergast and his ALS Ride for Life team to campus on Monday, May 16.

Neanderthals mated with modern humans much earlier than previously thought

May 17, 2016

Using several methods of DNA analysis, a research team has found strong evidence of interbreeding between Neanderthals and modern humans.

Why is autism more common in boys?

April 29, 2016

Ivan Iossifov talks about some of the reasons why autism disproportionately effects boys on a genetic level.

CSHL scientists Bo Li and Je Lee win HFSP Research Grant awards

April 12, 2016

Associate Professor Bo Li and Assistant Professor Je Lee, are among 25 teams that have won Human Frontier Science Program Research Program Grants

Where does autism come from when it doesn’t run in the family?

April 7, 2016

Associate Professor Ivan Iossifov discusses how parents who are not autistic can pass autism onto their children through their genes.

Neanderthals mated with modern humans much earlier than previously thought, study finds

February 12, 2016

Using several different methods of DNA analysis, an international research team has found what they consider to be strong evidence of interbreeding.

Finding huge promise in a single cell with student Robert Aboukhalil

November 2, 2015

Robert Aboukhalil use his skills as a computational biologist to make single-cell genomic data easy for scientists and clinicians to access and use.

Breaking down breast cancer at CSHL

October 30, 2015

A look at how several researchers at CSHL contribute to the field of breast cancer research.

Ride For Life gives $300,000 for ALS research at Cold Spring Harbor Laboratory (CSHL)

October 20, 2015

ALS Ride For Life this month presented $300,000 to CSHL Assistant Professor Molly Hammell and Associate Professor Josh Dubnau

Introducing the mighty Panoramix–defender of genomes!

October 15, 2015

Scientists have identified a protein the Piwi system uses to guide a cell's gene-silencing machinery to the right spots in the genome.

CSHL Fellow wins 2015 NIH Early Independence Award for cancer research

October 6, 2015

CSHL Lab Fellow Jason Sheltzer won the 2015 Early Independence Award from the National Institutes of Health High Risk, High Reward Research Program

Genetic analysis supports prediction that spontaneous rare mutations cause half of autism

September 22, 2015

Scientists find evidence suggesting that devastating “ultra-rare” mutations play a causal role in roughly half of all autism spectrum disorders.

Scientists sequence genome of worm that can regrow body parts, seek stem cell insights

September 21, 2015

Worm’s genome could lead to better understanding of its regenerative prowess and advance stem cell biology.

Mathematical ‘Gingko trees’ reveal mutations in single cells that characterize diseases

September 4, 2015

Online app could help clinicians choose the best treatments by comparing genetic fingerprints of individual cells.

12th annual LI2DAY Walk raises over $400,000

September 1, 2015

The $19,000 donation received by CSHL will support breast cancer research in the laboratory of Professor Alea Mills.

The biggest beast in the Big Data forest? One field’s astonishing growth is, well, ‘genomical’!

July 6, 2015

Scientists work to figure out how to capture, store, process and interpret all that genome-encoded biological information.

Seeking out cancer: From early detection to treatment

June 26, 2015

'Seeking Out Cancer: From Early Detection to Treatment' by Michael Wigler.

Scientists show the mammary gland ‘remembers’ prior pregnancy, spurring milk production

Anecdotal reports of nursing mothers have long suggested that giving milk is a lot easier in second and subsequent pregnancies.

Tumor cells that mimic blood vessels could help breast cancer spread to other sites

April 8, 2015

“Vascular mimicry” observed in mice could be helping tumors evade anti-angiogenesis drugs

Cold Spring Harbor Laboratory engages Hairpin Technologies Inc. to license its short hairpin RNA (shRNA) technology

March 31, 2015

Cold Spring Harbor Laboratory engaged Hairpin Technologies Inc. to expand the commercial distribution and research use of short hairpin RNA.

CSHL quantitative biologist Michael Schatz awarded 2015 Sloan Foundation Research Fellowship

February 20, 2015

Associate Professor Michael Schatz receives a 2015 Alfred P. Sloan Foundation Research Fellowship

Harnessing data from nature’s great evolutionary experiment

January 21, 2015

Scientists develop a computational method to estimate the importance of each letter in the human genome


Cancer Genetics and StemoniX Announce Merger Closing

CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of the Company.

Vyant Bio will be traded on the Nasdaq under the symbol VYNT beginning on March 31, 2021. The name and ticker change will align the Company’s strategic focus on the creation of a leading biotechnology and drug discovery platform business.

Vyant Bio is now positioned to integrate human-powered scientific and technology-based systems with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the Company’s proprietary pipeline. The merger of the two companies represents a bold new chapter in drug discovery, creating a unique platform using in vivo, in vitro, and in silico technologies to identify repurposed and novel therapeutics to fight diseases in neurology, oncology, and cardiology.

The merger has attracted highly experienced board and management team members who share a vision of creating world-class capabilities. Management teams from both companies will join forces for Vyant Bio, led by health science veteran Jay Roberts, who will serve as Chief Executive Officer, innovation thought-leader Ping Yeh, Vyant Bio’s new Chief Innovation Officer, and Andrew LaFrence, incoming Chief Financial Officer, an accomplished public company financial executive and former KPMG audit partner.

“Vyant Bio will now jumpstart an exciting clinical pipeline of therapeutics from its Drug Discovery Engine for purposes of out-licensing to partners worldwide,” stated Jay Roberts. “We worked tirelessly throughout 2020 and Q1 2021 to identify and complete this merger with StemoniX and are very excited to bring the best of these two companies together in a shared culture and vision for the future – to create safer and more effective therapeutics and meaningful shareholder value.”

“We are very pleased to be announcing the new name and branding initiative. Vyant Bio was created as it represents a vital, vibrant, innovative new force in drug discovery, derived from the French words “vie” and “avant” – together, they represent our mission to transform lives with new treatments derived from leading-edge science and technology. We believe the combined companies create a new path for innovation, with a human-powered approach that will de-risk and accelerate decision making to more rapidly bring important therapeutics to patients,” said Ping Yeh.

Under the terms of the merger agreement, the Company will issue an aggregate of 17,977,272 shares of its common stock to the former holders of StemoniX common stock, preferred stock, convertible notes and certain warrants. It will also issue options to purchase an aggregate of 893,179 shares of Common Stock to the holders of StemoniX options and warrants expiring in 2026 to purchase 143,890 shares of Common Stock to the holder of a StemoniX warrant.

Immediately after the merger, there were approximately 28,984,458 million shares of Common Stock of the Company outstanding.

H.C. Wainwright & Co. acted as financial advisor to Cancer Genetics, Inc., and Lowenstein Sandler LLP served as legal counsel to Cancer Genetics. Roth Capital Partners and Northland Capital Markets acted as financial advisors to StemoniX, and Taft Stettinius & Hollister LLP served as legal counsel to StemoniX.

A Current Report on Form 8-K containing more detailed information regarding the merger transaction will be filed with the Securities and Exchange Commission.

ABOUT VYANT BIO, INC.

Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The company will immediately begin to execute on the integration of these two leading businesses, to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients.

vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

For more information, please visit www.vyantbio.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio Inc.’s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.


Cancer Biology and Genetics

The Cancer Biology and Genetics (CBGN) cluster offers educational and research opportunities in the areas of cancer and the genetic and molecular basis of human disease within the Biomedical Sciences Graduate Program at Lewis Katz School of Medicine at Temple University (LKSOM). The CBGN cluster provides PhD, MD/PhD and MS students the opportunity to work with faculty from the Fels Research Institute at the School of Medicine and the Fox Chase Cancer Center (FCCC), as well as basic science and clinical departments at LKSOM. The membership of FCCC faculty in the CBGN cluster affords students the opportunity to undertake their research in FCCC laboratories. Students have their choice of numerous research laboratories at both LKSOM and FCCC to provide training in Cancer Biology, including mechanisms of transformation and tumorigenesis, signal transduction, the cell cycle and DNA repair using novel model systems and other cutting edge techniques. Other investigators studying the genetics and epigenetics of normal and diseased states use state-of-the-art genomic and epigenomic techniques and analyses. In addition to mechanistic studies, CBGN investigators are developing novel therapeutics for both the treatment and prevention of cancer and other diseases. Moreover, other CBGN members specialize in Cancer Prevention and Control and Cancer Immunology.

The CBGN cluster curriculum offers two advanced courses—Cancer Biology, and Genetics and Epigenetics. These courses build upon the concepts students learn in the biomedical science core curriculum. Moreover, this cluster also runs a vigorous Seminar Program with participation of students, faculty, postdoctoral fellows and invited speakers from the scientific community. The educational offerings together with the research opportunities within this cluster will allow interested students to gain the knowledge and research skills to position themselves at the forefront of tomorrow’s efforts to eradicate cancer.


DECEMBER 1 - Application Deadline

The PhD Program in Genetics, Genomics & Cancer Biology provides aspiring students with the background, training and experience necessary to launch careers as independent scientific investigators and scholars in the field of molecular genetics of disease, genomics and cancer biology. The Program is designed to take a multidisciplinary approach to the field by providing the student with a strong basic knowledge of genetics, biochemistry, cell biology and molecular biology, with additional exposure to other areas of related interest. Additionally, the Program provides sufficient flexibility so that graduating students can pursue research careers in either an academic or industrial setting.

Research laboratories are primarily located in the Bluemle Life Sciences Building. In addition to extensive basic equipment and facilities, the Program provides access to numerous specialized resources. These include facilities for cancer genomics, peptide synthesis and sequencing, cell sorting by flow cytometry, protein purification and characterization, microarray analyses and biomolecular imaging.

Curriculum

The Program is focused on research training, which begins in the first year as rotations in different laboratories, and continues as the student begins potential thesis projects in a chosen mentor's laboratory.